CFO at Trevi Therapeutics (TRVI) awarded 375,000 options Jan 8 2026

Rhea-AI Filing Summary

Trevi Therapeutics, Inc. reported that its Chief Financial Officer, David C. Hastings, received a grant of stock options on January 8, 2026. The award covers options to purchase 375,000 shares of common stock at an exercise price of $11.21 per share.

According to the disclosure, 25% of the underlying shares are scheduled to vest on January 8, 2027, with the remaining 75% vesting in equal monthly installments through January 8, 2030. Following this grant, the CFO is shown as beneficially owning 375,000 derivative securities directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HASTINGS DAVID C

(Last) (First) (Middle)

C/O TREVI THERAPEUTICS, INC.

195 CHURCH STREET, 16TH FLOOR

(Street)

NEW HAVEN CT 06510

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Trevi Therapeutics, Inc. [ TRVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$11.21	01/08/2026		A		375,000		(1)	01/07/2036	Common Stock	375,000	$0	375,000	D

Explanation of Responses:

1. This option was granted on January 8, 2026. The 375,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on January 8, 2027 and as to the remaining 75% of the shares in equal monthly installments thereafter through January 8, 2030.

	/s/ Christopher Galletta, attorney-in-fact	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Trevi Therapeutics (TRVI) report for its CFO?

Trevi Therapeutics reported that its Chief Financial Officer, David C. Hastings, was granted a stock option covering 375,000 shares of common stock on January 8, 2026, as disclosed on a Form 4.

What is the exercise price of the new Trevi Therapeutics (TRVI) stock options?

The stock option granted to the CFO has an exercise price of $11.21 per share for the underlying shares of Trevi Therapeutics common stock.

How do the Trevi Therapeutics (TRVI) CFO stock options vest?

The 375,000-share option is scheduled to vest as to 25% of the shares on January 8, 2027, with the remaining 75% vesting in equal monthly installments through January 8, 2030.

How many derivative securities does the Trevi Therapeutics (TRVI) CFO hold after this grant?

Following the reported transaction, the Form 4 shows the CFO beneficially owning 375,000 derivative securities (stock options) directly.

Was the Trevi Therapeutics (TRVI) CFO transaction a purchase or a grant?

The Form 4 identifies the transaction as a stock option grant to the CFO, coded as "A" (acquired) for derivative securities, rather than an open-market purchase.